Background. Human parvovirus B19 (B19V) infection and damage of circulating angiogenic cells (CAC) results in dysfunctional endogenous vascular repair (DEVR) with secondary end-organ damage. Trafficking of CAC is regulated by SDF-1α and the respective receptor CXCR4. We thus tested the hypothesis of a deregulated CXCR4/SDF-1α axis in symptomatic B19V-cardiomyopathy.
Patients with chronic human parvovirus B19 (B19V)-associated cardiomyopathy present with endothelial dysfunction [1] and cardiac ischemia due to coronary vasospasms despite patent coronary arteries [2, 3] . We have previously shown that targets of B19V infection include different types of bone marrow (BM)-derived regenerative circulating angiogenic cells (CACs) [4] , in addition to the well-known CD36 + erythroid progenitor cells [5] and endothelial cells [6] . Although B19V is a usually self-limiting subclinical disorder, in certain susceptible individuals B19V is associated with chronic myocardial presence of B19V and chronic cardiomyopathy [7] . The underlying mechanism is unclear.
The B19V genome encodes for the nonstructural protein NS1 and the 11 kDa protein, as well as for the capsid proteins VP1 and VP2 [8] . Although induction of apoptosis through NS1, VP1 [4] , and 11 kDa together with the underlying pathways have been manifold evidenced for different cell lines [9] , further interference with cellular pathways remains to be elucidated.
The regenerative potential of diverse subsets of CACs has been substantiated for reendothelialization and microvascular neovascularization with increased vascular density. Different cells are characterized as CACs by functional (ie, early outgrowth endothelial progenitor cells [eo-EPCs] or late outgrowth endothelial colony-forming cells [ECFCs] ) or surface markers (CD45 dim CD34 + KDR + or CD34 + KDR + ). Endothelial regeneration is a prerequisite for organ function [10] . In contrast to patients with progressive atherosclerotic disease [10, 11] , patients with B19V-associated endothelial damage present with increased numbers of albeit dysfunctional CACs [4, 12] . Notwithstanding this, reduced functional endothelial regenerative capacity is a characteristic feature of both patient groups [4, 10, 12] .
The axis of the chemokine stromal cell-derived factor 1α (SDF-1α or CXCL12) and its reciprocal receptor CXCR4 plays an essential role for the trafficking of CACs [13] [14] [15] . Increased numbers of CACs may be attributable to either enhanced mobilization or restricted homing capacity [15] . The transcription factor hypoxia-inducible factor 1α (HIF-1α) induces SDF-1α gene expression in ischemic tissue, leading to increased migration, homing, and adhesion of CXCR4-positive cells [16] . Increasing concentrations of SDF-1α have been shown to up-regulate CXCR4 in other cell lines [17, 18] , whereas SDF-1α-mediated down-regulation of CXCR4 may occur in human immunodeficiency virus type 1 (HIV-1) infection [19, 20] .
As our recent data suggested altered trafficking of CACs in patients with B19V cardiomyopathy [4, 12] , we tested the hypothesis of a virally induced up-or down-regulation of CXCR4 in CACs in vitro, as described for other viruses in CD4 + and CD4 -cells [21] [22] [23] [24] [25] . In addition, we investigated the CXCR4/SDF-1α axis in patients with B19V cardiomyopathy to analyze a potentially disrupted trafficking of CACs in myocardial B19V infection.
METHODS

Virus Stock and Infection, Flow Cytometry Protocols, Cell Lines and
Isolation of Primary Cells, Migration and CXCR4 Redistribution Assay, and
Transfection of ECFCs
All experiments were conducted as described previously [4, 6, 26, 27] . The detailed protocols can be found in the Supplementary Data.
Patients and Control Subjects
The total study population comprised 51 subjects prospectively recruited in our center. Thirty-one patients had chronic B19V cardiomyopathy, as defined previously [12] . For inclusion exclusion criteria and standard protocols [28, 29] , please see the Supplementary Data.
Of the above-recruited subjects, a subgroup of 30 individuals with clinical indications [30] for angiography and endomyocardial biopsy (EMB) was included into the study for invasive measurements of transcardiac gradients of CACs and chemokines, and simultaneous quantification of cardiac messenger RNA (mRNA) and progenitor cells. The study was approved by the local university ethics review board and was performed in accordance with the Declaration of Helsinki.
Circulating Chemokines
The circulating levels of stromal cell-derived factor 1α (SDF-1α/ CXCL12), vascular endothelial growth factor (VEGF), interleukin 10 (IL-10), interferon-γ-induced protein 10 (IP-10/CXCL10), and monocyte chemotactic protein 1 (MCP-1/CCL-2) were determined by multiplex enzyme-linked immunosorbent assay (ELISA) in serum samples using commercially available Bio-Plex Pro Kits (BioRad) according to the manufacturer's instructions.
Gene Expression Analysis for SDF-1α and HIF-1α
Differential gene expression for SDF-1α and HIF-1α mRNA was determined by real-time polymerase chain reaction (PCR) using a preamplification technique, as described previously [12] . For detection of SDF-1α and HIF-1α, we used the TaqMan Assays Hs00234140 and Hs00936371, respectively (both Applied Biosystems). Gene expression was normalized to hypoxanthine guanine phosphoribosyltransferase applying the delta-delta cycle threshold (Ct) method [31] .
Vascular Density and Cardiac Progenitor Cells in Endomyocardial
Biopsies
To determine the myocardial vascular density, we used an antibody against CD31 (dilution 1:100, Chemicon) and for the detection of cardiac progenitor cells (c-kit + CD45 -) antibodies against c-kit (dilution 1:50, DAKO) and CD45 (dilution 1:50; DAKO). Progenitor cells were identified as c-kit + in the absence of the marker CD45. As secondary antibody, we used an EnVision peroxidase-conjugated antimouse antibody (DAKO). Nuclei were subsequently stained with hemalam. For further details, please see the Supplementary Data.
Statistical Analysis
All in vitro experiments were carried out as at least 2 technical replicates (on average 3) technical replicates and 3 independent examples. Statistical significance was assumed if a null hypothesis could be rejected at P ≤ .05. All statistical analysis was performed with SPSS version 21.0 software. For further details, please see the Supplementary Data.
RESULTS
B19V Infection Enhances CXCR4 Expression and Migratory Capacity of CACs
As B19V has been shown to infect CACs and influence their numbers and function [4] and because the SDF-1α/CXCR4 axis is essential to trafficking of CACs, we studied the effect of B19V infection on the 2 relevant cell lines, eo-EPCs and ECFCs, with regard to CXCR4 receptor expression and functional chemokinetic activity with and without SDF-1α preincubation, and dissected the role of the individual contributing B19V genes. First, we investigated the effect of B19V infection on CXCR4 expression of CACs, followed by experiments to analyze the effect of additional SDF-1α preincubation and the following effects on chemokinesis.
CXCR4, as measured by flow cytometry, demonstrated a doubling of surface (P < .05) and total CXCR4 (P < .001; Figure 1A ) after in vitro B19V infection in eo-EPCs 24 hours postinfection compared to controls. CXCR4 expression in total (P < .01) and on the cell surface (P < .001; Figure 1A ) was further increased 4-fold 48 hours postinfection compared to controls. Similar to the results for eo-EPCs, expression of CXCR4 on the surface of ECFC increased 1.75-fold (P < .05) and doubled in total (P < .01) 24 hours after B19V infection ( Figure 1B) .
To affirm that increased CXCR4 expression translates into increased chemokinetic capacity in the presence of SDF-1α after B19V infection, a chemokinesis assay was performed with both cell lines. The chemokinetic activity of both cell types with or without infection increased with addition of SDF-1α (P < .01) compared to basal medium. In the control setting, B19V infection on its own resulted in an increased baseline migratory activity of 39% in eo-EPCs (P < .001) and 48% in ECFCs (P < .01) compared to noninfected cells (no SDF-1α; Figure 1C and 1D). Addition of SDF-1α increased the B19V-induced transwell migratory capacity significantly by 49% in eo-EPCs (P < .01) and 78% in ECFCs (P < .001) compared to uninfected cells ( Figure 1C and 1D) . The migratory activity of uninfected eo-EPCs (P < .001) in the presence of SDF-1α increased by nearly 50% compared to basal medium. Taken together, these data imply an increased chemokinetic capacity of B19V-infected vs noninfected CACs through a B19V-induced increment of CXCR4. In ECFCs, we cannot exclude proliferation as a potential confounding contributor to increased numbers of transwell cells.
Overexpression of B19V VP2 in ECFC Is Associated With CXCR4 Surface Expression and Migration
To dissect the role of the individual B19V genes for alterations of surface CXCR4 expression, we transfected ECFCs (Supplementary Data) with expression plasmids for B19V genes, namely NS1, 11 kDa protein, VP1, and VP2. The empty expression vector pcDNA served as a control. Transfection of ECFC resulted in a transfection efficiency of approximately 21% [4] . Due to restrictions in liposomal transfection efficiency of eo-EPCs [4] , experiments were carried out with ECFCs only.
CXCR4 expression strongly increased 24 hours posttransfection on transfected ECFCs. VP2 showed the strongest, 22-fold induction of CXCR4 expression compared to control (P < .001; Figure 3A ). Furthermore, the VP2-induced increase of CXCR4 compared to control was significantly more pronounced than for VP1 (15.7-fold), 11 kDa protein (13.3-fold), and NS1 (8-fold) (all P < .001; Figure 2A) .
We have recently shown that the B19V proteins NS1 and 11 kDa induced up to 85% apoptosis in transfected ECFCs, measured by active caspase-3, with lowest values (38%) for VP2 [4] . To exclude measuring intracellular CXCR4 due to degradation of cellular membranes in late apoptosis, we gated on different subpopulations of transfected ECFCs depending on annexin V and propidium iodide (PI). Expectedly, indicating intracellular measurement, CXCR4 values increased in the subfraction of ECFCs in late apoptosis (annexin V + PI + ) compared to nonapoptotic cells (annexin V -PI -) (pcDNA: 9-fold; NS1: 19-fold; 11 kDa: 38-fold; VP1: 34-fold; and VP2: 42-fold; data not shown). Consequently, a high proportion of CXCR4 measured in the total ECFC population after transfection relates to this effect. To exclude this bias, we gated on cells during early apoptosis (annexin V + PI -) only. Here, solely VP2 induced a 2.8-fold increase of surface CXCR4 compared to control transfection (P < .001; Figure 2B ) and a 7.8-fold increase compared to nonapoptotic cells (annexin V -PI -; P < .005; data not shown). A functional chemokinetic migration assay of VP2-transfected ECFCs in the presence of SDF-1α confirmed a 22% increased transwell migration compared to control transfected ECFCs (P < .001; Figure 2C ). Mere transfection with VP2 had no effect on chemokinetic activity.
We next investigated the effect of chronic B19V infection on CAC trafficking in vivo. Because B19V is strictly human pathogenic and no convincing animal model exists to analyze the effect of B19V on CACs, we chose patients with chronic B19V Translocated cells in the transwell assay with endothelial growth factor medium 2 (EGM-2) only or EGM-2 with 10 nmol/L SDF-1α for a further 24 hours were stained with human plasma low density lipoprotein, acetylated & dil-labeled and counted by immunofluorescence microscopy. Data are mean ± standard deviation. All experiments were conducted as at least 5 (eo-EPCs) or 3 (ECFCs) independent experiments. *P < .05; **P < .01; ***P < .001.
cardiomyopathy as a model. By examining the numbers of CACs, their migratory function, chemokine levels, and migration of CACs into the heart, as well as numbers of cardiac progenitor cells and microvascular density, we tested the effect of B19V infection on trafficking of CACs in humans.
Patient Characteristics of the B19V Cardiomyopathy Study
The baseline characteristics of the total population with 51 subjects, comprising 31 patients with chronic B19V cardiomyopathy and the respective 20 control subjects, are summarized in Table 1 . Compared to controls, patients with B19V cardiomyopathy suffered more often from atypical chest pain, and were otherwise similar regarding baseline demographic and clinical characteristics, as well as number of cardiovascular risk factors and concomitant medication. The baseline characteristics of the subgroup of 30 patients with measurements of transcoronary gradients (16 patients with B19V cardiomyopathy and 14 control subjects) are summarized in the Supplementary Table.
Increased Numbers of CACs and Reduced Migratory Capacity in B19V Cardiomyopathy
From the subsets of CACs, CD34 + KDR + cells have been uniformly shown to influence and reflect cardiovascular disease in patients with coronary artery disease [10] . Similar to our previous results [4, 12] , in this larger cohort of patients with B19V cardiomyopathy, there were 2.9-fold higher numbers of CD45 dim CD34 + KDR + cells compared with controls (P < .05). Furthermore, an immature subset, characterized by the coexpression of CD133 and KDR, was significantly increased 2.9-fold in patients with B19V cardiomyopathy (P < .01; Figure 3A ) compared with controls. To dissect a down-regulation of CXCR4 in B19V cardiomyopathy as indicator of impaired functional and migratory capacity of cells participating in vascular regeneration [32] , we quantified CXCR4 surface expression on CD34 + KDR + cells. Patients with B19V cardiomyopathy presented with 72% reduced numbers of CXCR4 + CD34 + KDR + cells (P < .05; Figure 3B ). Indeed, confirming reduced migratory capacity in patients with B19V cardiomyopathy, there was a 40% reduced migration with SDF-1α compared with healthy controls (P < .05; Figure 3C ).
Patients With B19V Cardiomyopathy Show Elevated Chemokine Levels
We next analyzed whether increased numbers of CACs were attributable to serum VEGF and SDF-1α levels, leading to enhanced mobilization. Patients with B19V cardiomyopathy had significantly 4.3-fold higher SDF-1α levels compared with controls (P < .05; Figure 3D ), but similar VEGF levels (data not shown). IP-10 is known to parallel viral diseases and end-organ damage [33] and acts as chemoattractant. We thus additionally quantified IP-10 serum concentrations, and showed IP-10 levels to be twice as high in patients with B19V cardiomyopathy compared with controls (P < .05; Figure 3D ).
Transcardiac Gradients Show a Retention of CACs With Increased Cardiac SDF-1α
Having shown an increase of peripherally circulating CD45 dim CD34 + KDR + cells in B19V cardiomyopathy, we examined whether these cells might migrate into the heart through simultaneous sampling of the aorta and the coronary sinus in all patients (transcardiac gradient [TCG]) as described previously [28, 29] . Only in patients with B19V cardiomyopathy, a transcardiac reduction of CD45 dim CD34 + KDR + cells of -47% (-15% to -62%; 95 CI; P < .01; Figure 4A ) was observed in the great cardiac vein compared to the aorta, in contrast to controls (P < .001).
As SDF-1α is a potent chemoattractant in ischemic and in virus-negative inflammatory cardiomyopathy [15, 16] , SDF-1α mRNA was quantified in EMB in these study patients. Reinforcing that indeed retention of CACs relates to reduced numbers after transcardiac passage, SDF-1α mRNA concentrations from endomyocardial biopsies were 2.8-fold elevated in B19V cardiomyopathy compared with controls (P < .05; Figure 4B ).
As cardiac regeneration is attributable to BM-derived CACs and, as recently evidenced, also to resident cardiac stem cells [34, 35] , intracardiac ckit + cells were quantified. Patients with B19V cardiomyopathy had significantly 73% lower numbers of ckit + cardiac stem cells compared to controls (P < .05; Figure 4C ).
SDF-1α as Single Independent Predictor for Elevated CD34 + KDR + Cells
A multivariate analysis for the entire study group (n = 51) demonstrated a correlation of the following serum chemoattractants with CD133 + KDR + or CD45 dim CD34 + KDR + cells: (1) SDF-1α with CD133 + KDR + cells (r = 0.46, P = .027; data not shown) and with CD45 dim CD34 + KDR + cells (r = 0.40, P < .05; Figure 5A ); (2) VEGF with CD133 + KDR + cells (r = 0.43, P = .04) and with CD45 dim CD34 + KDR + cells (r = 0.55, P < .002); (3) IL-10 with CD133 + KDR + cells (r = 0.67, P < .0001); and (4) IP-10 with CD133 + KDR + cells (r = 0.422, P = .045). Data for (1-4) are not shown. Apart from these, no other correlations were detectable between serum chemokines and the above-mentioned CACs.
For the subgroup of patients with available TCG and endomyocardial biopsies (n = 30), there were the following correlations: (1) SDF-1α mRNA with CD133 + KDR + cells (r = 0.46, P = .058; data not shown) and with CD45 dim CD34 + KDR + cells (r = 0.45, P = .015; Figure 5B ); (2) HIF-1α mRNA with CD45 dim CD34 + KDR + cells (r = 0.375, P = .05). Expectedly, SDF-1α mRNA and HIF-1α mRNA intercorrelated significantly (r = 0.51, P = .012; data not shown), pointing toward an ischemia-triggered up-regulation of SDF-1α mRNA.
Furthermore, the correlation between TCG of serum SDF-1α and of CD45 dim CD34 + KDR + cells (P = .059), as well as the TCG of serum SDF-1α and myocardial SDF-1α mRNA showed a strong trend (P = .069).
After multivariate analysis, serum SDF-1α was the single independent predictor for elevated CD45 dim CD34 + KDR + cells (ß: 0.42, T: 2.3; P = .029), whereas no such predictor was found for numbers of CD133 + KDR + -cells. These data show the strong role for the up-regulation of cardiac SDF-1α, regulating CAC trafficking in B19V cardiomyopathy with enhanced mobilization and homing to the heart.
There was no correlation of chemokines with CXCR4 expression on CD34 + KDR + cells.
B19V-Positive Patients Show Reduced Cardiac Vascular Density
Patients with B19V cardiomyopathy presented with a significantly 77% reduced cardiac vascular density (P < .05; Figure  5C ) compared to controls. Cardiomyocyte atrophy as well as hypertrophy is seen in B19V cardiomyopathy; however, mean cardiomyocytes diameters lie in the normal range. Because impaired left-ventricular ejection fraction (LVEF) is associated with reduced vascular density and consequent depressed coronary flow reserve [36] , we sought to exclude LVEF as a confounder between patients with B19V cardiomyopathy and healthy controls. There was a weak, but significant correlation of LVEF and vascular density (r = 0.32, P < .05), with a significantly (P < .05) reduced vascular density in impaired (≤40%, n = 9) LVEF ( Figure 5D ). Presence of B19V cardiomyopathy and reduced LVEF were included in a multivariate analysis as independent predictors of reduced vascular density. Here, presence of B19V remained the single independent predictor for reduced cardiac vascular density (ß = 0.43, T = 2.2, P = .039). There was no correlation of vascular density and numbers of cardiac progenitor cells or TCG of any of the CACs.
DISCUSSION
Patients with chronic B19V cardiomyopathy and cardiac ischemia [2] have significantly increased numbers of circulating CD34 + KDR + cells [12] . The finding of an increased CAC count in the setting of chronic B19V infection thus prompted our investigations for a deranged mobilization and homing of endogenous circulating regenerative cells.
The results of this study demonstrate that B19V infection modifies the migratory capacity of the heterogeneous group of CACs. Indeed, patients with B19V cardiomyopathy present with a deranged CXCR4/SDF-1α axis. In these patients, high systemic serum SDF-1α levels were associated with a systemic increase of circulating angiogenic CD45 dim CD34 + KDR + cells. Following elevated intracardiac SDF-1α, CD45 dim CD34 + KDR + continuously migrated into the myocardium in B19V cardiomyopathy.
In vitro infection of different CACs with B19V resulted in a significantly increased surface CXCR4 expression compared to control cells, paralleled by an enhanced migratory capacity. Our findings are in contrast to the extensively studied viral down-regulation of surface CXCR4 after productive HIV infection, where CXCR4 permits HIV entry [21] , as well as after herpes simplex virus type 1 and human herpesvirus infections [25] . Increasing concentrations of SDF-1α have been shown to up-regulate CXCR4 in other cell lines [17, 18] and consequently promote angiogenesis. Interestingly, CXCR4 expression and chemokinetic function, or possibly proliferation in ECFCs, of CACs was further increased with raising concentrations of SDF-1α after B19V infection. This is in contrast to previously described reports for the SDF-1α-mediated down-regulation of CXCR4 on other cell lines, that is, endothelial cells and CD4 + T lymphocytes in HIV-1 infection [19, 20] . Although addressing the potential mechanism for increased CXCR4 in the presence of SDF-1α in B19V infection was beyond the scope of our work, different mechanisms can be envisaged [23, 37, 38] . Furthermore, transcriptional targeting of the CXCR4 promoter, as seen in carcinoma cells, could be an explanation [39] . Increased SDF-1α, as induced in B19V cardiomyopathy, could lead to an increased retention in the BM niche as well as migration of B19V-infected CACs with elevated CXCR4 surface expression into cardiac tissue. This effect could be a strategy to engage the SDF-1/CXCR4 axis for spreading of B19V throughout the body and directing CACs to organs with enhanced SDF-1a at a time of high SDF-1 expression [16] .
The data of this study show that VP2 is associated with CXCR4 surface expression underlying the increased migratory capacity of CACs toward SDF-1α. No further conclusions regarding direct or indirect contributors can be drawn from our data. It is rather likely that multiple gene products contribute to this effect.
In contrast to our in vitro data as model for an acute B19V infection, surface CXCR4 expression on blood CD34 + KDR + cells and migratory capacity of blood eo-EPCs were reduced in patients with chronic B19V cardiomyopathy. In these patients, increased numbers of CACs were associated with a systemic increase of several potential mobilizing factors. However, on multivariate analysis, serum SDF-1α remained the sole independent predictor for increased numbers of CACs. The magnitude of plasma elevation of SDF-1α is a tightly synchronized process regulating the mobilization of proangiogenic cells and the extent of revascularization [15] , with a close correlation to CAC numbers [40] . We postulate that the increased numbers of CACs in this disease are attributable to a complex de-regulation of the CXCR4/SDF-1α axis with a combination of increased mobilization and prolonged dwelling of dysfunctional CACs with impaired homing capacity.
The CXCR4/SDF-1α axis not only mediates mobilization into the circulation, but is also involved in recruitment and retention of CACs [15] for adult neovascularization in the setting of cardiac ischemia [13] . Ischemia of myocardial tissue is the most potent stimulus for HIF-1α-induced SDF-1α expression. To further elucidate an ischemia-triggered de-regulation of the CXCR4/SDF-1α axis, we measured cardiac concentrations of HIF-1α and SDF-1α in these patients. Our data provide further evidence for the up-regulation of cardiac SDF-1α through HIF-1α in B19V cardiomyopathy. This was associated with a negative transcardiac gradient of CACs, indicating a continuous migration of CACs into the heart in this disease. In addition to recruitment of CACs, resident cardiac progenitor cells contribute to endogenous cardiac regeneration. Indeed, in patients with B19V cardiomyopathy, numbers of cardiac progenitor cells with endothelial phenotype and microvascular density as a surrogate for an impaired microvascular regeneration were reduced. Presence of B19V was the single independent predictor for reduced vascular density, whereas sole presence of reduced LVEF could be excluded. These results demonstrate the importance of B19V infection for reduced coronary blood flow leading to ischemia and endothelial dysfunction. B19V-induced increased CXCR4 in CACs leads to their enhanced retention in the BM. In B19V infection, uninfected CACs adjacent to infected CACs undergo apoptosis, and endogenous proliferation and mobilization of uninfected CACs occur in vivo [4] . Consequently, disturbed endothelial regeneration of the cardiac endothelial layer leading to cardiac ischemia induces locally increased myocardial expression of the key regulator SDF-1α and to further activation of mechanisms enhancing release of CACs from BM [16] . Once CACs are mobilized and circulating in the blood, increased CXCR4 privileges B19V-infected cells for retention/recruitment of CACs in/to ischemic tissue, facilitated by the increased myocardial SDF-1α gradient. B19V-infected CACs however, are doomed cells that undergo apoptosis [4] with underwhelming regenerative capacity. Thus, although B19V-infected CACs have a higher potential to home to myocardial tissue, they are dysfunctional, leading to a further need for proliferation and mobilization of a probably finite pool of CACs in the BM.
In conclusion, the B19V-induced de-regulation of the CXCR4/SDF-1α axis with retention of BM-derived B19V-infected CACs to diverse tissues offers an explanation for the seemingly consistent persistence of B19V for many years in organs with restricted B19V replication capacity. In the context of therapeutic engineering, it will be a challenge to identify the responsible domain of B19V VP2 to modify trafficking without compromising the function of progenitor or other angiogenic cells. benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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